FDA approves Merck’s clesrovimab infant RSV prevention (MK‑1654)?
$22,545 Vol.
Rules
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Merck’s biologics license application (BLA) for clesrovimab (MK‑1654) as a preventive treatment for respiratory syncytial virus (RSV) in infants by June 17, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No".
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL), explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL), explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
Created At: Jun 8, 2025, 7:17 PM UTC
Volume
$22,545End Date
Jun 17, 2025Created At
Jun 8, 2025, 7:17 PM UTCResolver
0x6A9D22261...Outcome proposed: Yes
No dispute
Final outcome: Yes
$22,545 Vol.
FDA approves Merck’s clesrovimab infant RSV prevention (MK‑1654)?
About
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Merck’s biologics license application (BLA) for clesrovimab (MK‑1654) as a preventive treatment for respiratory syncytial virus (RSV) in infants by June 17, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No".
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL), explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL), explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
Volume
$22,545End Date
Jun 17, 2025Created At
Jun 8, 2025, 7:17 PM UTCResolver
0x6A9D22261...Outcome proposed: Yes
No dispute
Final outcome: Yes
Beware of external links.
Beware of external links.




Beware of external links.
Beware of external links.